E-mail: Jana.Markova@uhkt.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- CBFβ/MYH11 Hypomethylation Signature In Patients With Acute Myeloid Leukaemia
- DIFFERENTIAL DNA METHYLATION IN AML PATIENTS WITH WILD-TYPE AND MUTATED DNMT3A AND PROGNOSTIC IMPACT OF DNA METHYLATION
- DNMT3A MUTATIONS IN INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA
- EXPRESSION OF WT-1, PRAME, RHAMM AND BAALC GENES IN PERIPHERAL BLOOD OF AML PATIENTS AT DIAGNOSIS
- Expression Pattern of WT1 Isoforms in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Severe Aplastic Anemia (SAA)
- CHRONIC MYELOPROLIFERATIVE DISORDERS WITH THROMBOCYTHEMIA: THROMBOSIS ASSOCIATED WITH INHERITED THROMBOPHILIA OR JAK2 V617F GENE MUTATION
- IDH1 (BUT NOT IDH2) MUTATIONS CAUSE INFERIOR OUTCOME IN PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETICS
- Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin
- IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL
- JAK2 V617F MUTATION SCREENING IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS AND CORE BINDING FACTOR ACUTE MYELOID LEUKEMIAS (CBF-AML)
- MONITORING OF MRD IN PERIPHERAL BLOOD OF AML PATIENTS BY QUANTITATIVE ESTIMATION OF WT-1 LEVEL
- MUTATIONS OF ASXL1 GENE IN PATIENTS WITH AML WITH AN INTERMEDIATE-RISK CYTOGENETIC PROFILE
- Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group
- Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results
- SECONDARY GENETIC ABERRATIONS AND THEIR EFFECT ON PROGNOSIS IN CORE BINDING FACTOR - ACUTE MYELOID LEUKEMIA (CBF-AML)
- THE DIFFERENCES IN PROGNOSTIC OUTCOME BETWEEN AML1/ETO AND CBFb/MYH11 POSITIVE AML PATIENTS
- THE IMPACT OF LENGTH AND INTEGRATION SITE OF THE INTERNAL TANDEM DUPLICATION OF FLT3 GENE ON THE CLINICAL OUTCOME OF PATIENTS WITH AML
- THREE CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIAS (CBF-AML) IN A SINGLE PATIENT
- WHOLE GENOME AND TARGETED BISULFITE SEQUENCING REVEALS 3 DNA METHYLATION CLUSTERS AND NEW BIOLOGICALLY RELEVANT HYPERMETHYLATED GENES IN AML PATIENTS
